The success of neoadjuvant immunotherapy trials like Niagara and those with EV-Pembro means most patients will receive immune therapy before surgery. This fundamentally shifts the clinical landscape, making the question of starting adjuvant immunotherapy less relevant as perioperative treatment becomes the standard.

The INVIGOR-11 trial data should be applied carefully. A positive ctDNA result post-surgery indicates when to *initiate* adjuvant immunotherapy. However, if a patient on neoadjuvant therapy becomes ctDNA-negative, this signals treatment efficacy and is a reason to *continue* the planned course, not a justification for stopping it early.

Short-duration preoperative studies (e.g., SALTY ELLIPSE, SERENA-three) use molecular changes like Ki67 reduction, not tumor shrinkage, as primary endpoints. This provides rapid, cost-effective proof of biologic activity and helps optimize dosing for massive, long-term adjuvant trials.

The rapid adoption of neoadjuvant immunotherapy as the superior standard of care means this new adjuvant vaccine faces an uphill battle for relevance. Its true future impact hinges on proving its efficacy when combined with neoadjuvant therapy, a combination that could potentially lead to unprecedentedly low relapse rates for patients.

The current pace of innovation in CLL treatment means new options become available faster than long-term clinical trials can conclude. This creates a critical need for more efficient trial designs and validated intermediate endpoints that can provide reliable answers sooner.

Data from trials like CheckMate 816 shows that achieving a Pathologic Complete Response (PCR) after neoadjuvant chemo-immunotherapy is a powerful early surrogate endpoint. Patients with PCR demonstrate markedly improved overall and event-free survival.

The failure of the Checkmate 914 adjuvant trial, which used a six-month duration of nivolumab plus ipilimumab, suggests this shorter treatment window may be inadequate. In contrast to positive trials with one year of therapy, this outcome indicates that treatment duration is a critical variable for achieving a disease-free survival benefit in the adjuvant RCC setting.

While KEYNOTE-905 showed dramatic survival benefits with neoadjuvant plus adjuvant EV-pembrolizumab, its design makes it impossible to isolate the benefit of each phase. The high (57%) pathologic complete response after neoadjuvant therapy alone suggests many patients may be overtreated with adjuvant cycles, risking unnecessary long-term toxicity like neuropathy.

Unlike chemotherapy, neoadjuvant immunotherapy appears more effective than adjuvant therapy because it leverages the in-situ tumor and its associated lymph nodes as a 'training ground.' This allows the immune system to generate a robust, specific anti-tumor response before the primary tumor and nodal basin are surgically removed.